MAOA and pulmonary arterial hypertension: Preliminary observations from Sun and colleagues demonstrate that expression of MAO-A is upregulated in PAH patients [161] and that the MAO-A inhibitor clorgyline partially reverses indices of PH in a PAH rat model (SU5416/hypoxia), including RVSP, RV hypertrophy and PA remodeling [161,162].